Triomics has announced a $22 million Series B financing round led by Battery Ventures, increasing the company’s total funding to more than $36 million. The round included participation from existing investors Lightspeed, Nexus Venture Partners, and Y Combinator, alongside strategic healthcare investors Oncology Ventures and Precision Health Informatics, a subsidiary of Texas Oncology.
Founded in 2021 by Sarim Khan and Hrituraj Singh, Triomics develops AI infrastructure designed specifically for oncology workflows. The company’s platform replaces labor-intensive manual chart review processes by using specialized AI agents to analyze complex, unstructured clinical data, including longitudinal patient records, pathology reports, radiology findings, biomarker data, and treatment histories.
The financing will be used to expand Triomics’ engineering organization, accelerate deployment across healthcare systems, and support broader adoption among provider organizations and life sciences companies.
The company is addressing a longstanding challenge in oncology, where clinicians, researchers, and support staff often spend significant time manually reviewing patient records for clinical trial eligibility, registry reporting, and care coordination. As cancer records become increasingly complex and clinical trial criteria continue to evolve, healthcare organizations face growing operational burdens associated with extracting actionable information from large volumes of data.
Triomics’ platform is designed to generate structured outputs from patient records while maintaining traceability to original source documents. According to the company, every recommendation produced by its AI agents can be verified within existing clinical workflows.
“Oncology is the hardest place to build AI, yet the most important,” stated Hrituraj Singh, co-founder and CTO of Triomics. “Getting a model to reason reliably across thousands of pages of notes, pathology, imaging, and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use.”
The platform has been adopted by several leading cancer centers and healthcare organizations, including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Yale Cancer Center, Mount Sinai Tisch Cancer Center, and Texas Oncology.
Triomics also cited peer-reviewed validation published in Nature Digital Medicine and presented at the American Society of Clinical Oncology (ASCO), demonstrating measurable operational benefits:
67% reduction in manual chart review time
40% increase in clinical trial matches
More than 30% increase in trial enrollment
In addition to trial matching and clinical workflows, the company is expanding into cancer registry abstraction and regulatory reporting. Battery Ventures Principal Brandon Gleklen, who will join the company’s board, noted that the same AI infrastructure can support clinical trial matching, pre-visit chart preparation, and registry abstraction without requiring separate integrations, providing a scalable foundation for oncology-focused healthcare operations.
Click here for the original news story.
